Clinical Trials in Austin

Showing 6761-6780 of 11,561 trials

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04128293

This is an open-label, single-dose, four-period, four sequential, and crossover study conducted to assess the relative bioavailability of GSK3640254 mesylate tablets and GSK3640254 mesylate capsules (in the presence of a moderate fat meal). This study will also evaluate the effect of food (fasted, moderate fat meal, and high fat meal) on the pharmacokinetics of GSK3640254 mesylate tablet formulation. Participants will be randomized to receive a single dose of GSK3640254 200 milligram (mg) capsules under moderate fat conditions and GSK3640254 200 mg tablets under moderate fat, fasted and high fat conditions in each treatment period. Approximately 16 participants will be enrolled and the duration of the study will be approximately 54 days.

HIV Infections

ViiV Healthcare16 participantsStarted Oct 2019

Austin, Texas, United States

COMPLETEDPhase 3< 1 mile

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Enstilar® Foam (LEO Pharma Inc.) in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis)

Psoriasis Vulgaris

Glenmark Pharmaceuticals Ltd. India494 participantsStarted Oct 2018

Encinitas, California, United States • Fountain Valley, California, United States • San Diego, California, United States +27 more locations

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

Find Trials by Condition in Austin

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Efficacy of CES in New Mothers During the Post Partum Period

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05